Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEMOX Neoadjuvant Therapy for Resectable Intrahepatic Cholangiocarcinoma
NCT04523402Phase 2Unknown
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Start
- Dec 2020
- Primary completion
- Dec 2022
- Modality
- DNA Intercalators/Alkylators
01
Overview
A Phase 2 trial of gemcitabine, oxaliplatin in intrahepatic cholangiocarcinoma (ICC), sponsored by Eastern Hepatobiliary Surgery Hospital. Status: unknown.
02
Drugs
gemcitabineoxaliplatin
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT04523402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04523402.